华海药业
(600521)
| 流通市值：230.13亿 | | | 总市值：230.13亿 |
| 流通股本：14.97亿 | | | 总股本：14.97亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 4,912,824,963.41 | 2,335,389,955.12 | 8,587,145,652.08 | 6,408,881,906.05 |
| 营业收入 | 4,912,824,963.41 | 2,335,389,955.12 | 8,587,145,652.08 | 6,408,881,906.05 |
| 二、营业总成本 | 4,348,073,997.35 | 2,158,801,767.76 | 8,145,904,767.72 | 5,972,319,712.38 |
| 营业成本 | 2,043,439,092.74 | 988,642,341.82 | 3,421,513,359.52 | 2,454,250,665.3 |
| 税金及附加 | 69,924,927.32 | 37,688,887.26 | 111,126,035.14 | 88,448,434.47 |
| 销售费用 | 927,588,290.22 | 474,960,126.59 | 1,577,067,587.51 | 1,288,862,031.04 |
| 管理费用 | 639,305,215.52 | 335,114,640.18 | 1,558,912,337.62 | 1,143,453,880.19 |
| 研发费用 | 462,997,490.94 | 218,541,426.16 | 1,229,124,707.86 | 829,481,556.27 |
| 财务费用 | 204,818,980.61 | 103,854,345.75 | 248,160,740.07 | 167,823,145.11 |
| 其中:利息费用 | 121,561,791.48 | 63,105,997.24 | 233,603,535.29 | 175,541,052.72 |
| 其中:利息收入 | 13,656,664.19 | 6,221,223.54 | 25,828,430.93 | 20,318,023.01 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 9,596,469.37 | 4,775,138.5 | 48,739,845.24 | 59,175,336.21 |
| 加:投资收益 | 211,124,981.07 | 243,149,935.34 | 18,800,442.18 | 17,342,857.27 |
| 资产处置收益 | 23,330,595.34 | 14,258.78 | 943.66 | -2,695,052.37 |
| 资产减值损失(新) | -18,906,386.57 | -8,253,812.66 | -205,463,675.96 | -70,395,040.05 |
| 信用减值损失(新) | -6,844,229.57 | -13,026,922.58 | 9,033,654.44 | 4,119,100.99 |
| 其他收益 | 71,278,616.07 | 40,891,513.52 | 144,109,248.65 | 111,048,572.62 |
| 四、营业利润 | 854,331,011.77 | 444,138,298.26 | 456,461,342.57 | 555,157,968.34 |
| 加:营业外收入 | 2,435,658.38 | 1,195,295.35 | 15,157,660.24 | 12,636,565.55 |
| 减:营业外支出 | -45,268,580.7 | 1,000,027.44 | 27,741,930.81 | 18,637,791.5 |
| 五、利润总额 | 902,035,250.85 | 444,333,566.17 | 443,877,072 | 549,156,742.39 |
| 减:所得税费用 | 134,947,142.84 | 45,992,125 | 216,547,678.89 | 175,226,638.46 |
| 六、净利润 | 767,088,108.01 | 398,341,441.17 | 227,329,393.11 | 373,930,103.93 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 767,088,108.01 | 398,341,441.17 | 227,329,393.11 | 373,930,103.93 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 770,910,153.52 | 404,175,569.82 | 266,399,456.11 | 380,356,337.29 |
| 少数股东损益 | -3,822,045.51 | -5,834,128.65 | -39,070,063 | -6,426,233.36 |
| 扣除非经常损益后的净利润 | 426,323,271.21 | 136,031,977.67 | 157,551,579.54 | 270,050,885.01 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.52 | 0.27 | 0.18 | 0.26 |
| (二)稀释每股收益 | 0.52 | 0.27 | 0.18 | 0.26 |
| 八、其他综合收益 | -12,927,589.98 | -1,212,216.33 | -4,256,027.25 | -343,912.19 |
| 归属于母公司股东的其他综合收益 | -13,185,920.67 | -1,674,732.59 | -4,475,829.61 | -438,740.6 |
| 九、综合收益总额 | 754,160,518.03 | 397,129,224.84 | 223,073,365.86 | 373,586,191.74 |
| 归属于母公司股东的综合收益总额 | 757,724,232.85 | 402,500,837.23 | 261,923,626.5 | 379,917,596.69 |
| 归属于少数股东的综合收益总额 | -3,563,714.82 | -5,371,612.39 | -38,850,260.64 | -6,331,404.95 |
| 公告日期 | 2026-08-27 | 2026-04-30 | 2026-04-30 | 2025-10-31 |
| 审计意见(境内) | | | 标准无保留意见 | |